SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 366.92 |
| Enterprise Value ($M) | 414.97 |
| Book Value ($M) | -14.64 |
| Book Value / Share | -0.83 |
| Price / Book | -25.07 |
| NCAV ($M) | -47.59 |
| NCAV / Share | -2.70 |
| Price / NCAV | -7.71 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.05 |
| Return on Assets (ROA) | 0.03 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.81 |
| Current Ratio | 1.96 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 106.47 |
| Assets | 139.42 |
| Liabilities | 154.06 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | |||
| 13G/A | Soleus Capital Master Fund, L.P. | |||
| 13G/A | Invesco Ltd. | |||
| 13G | BlackRock, Inc. | |||
| 13G/A | Vanguard Group Inc | 5.13 | -25.91 | |
| 13G | Morgan Stanley | 8.30 | ||
| 13G/A | Goldman Sachs Group Inc | 0.10 | -97.27 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 29,807 | 111,733 | 26.68 | |
| 29,865 | 84,970 | 35.15 | |
| 49,978 | 130,915 | 38.18 | |
| 42,523 | 136,844 | 31.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| REPL – Replimune Group, Inc. | RGEN – Repligen Corporation |
| RGNX – REGENXBIO Inc. | RLMD – Relmada Therapeutics, Inc. |
| RLYB – Rallybio Corporation |